Anti-type I interferon antibodies as a cause of severe COVID-19.
Anti-type I interferon antibodies as a cause of severe COVID-19.
复制标题
DOI：
10.12703/r-01-0000010
复制
发表时间：
2022-01-01
期刊：
影响因子：
--
通讯作者：
Zanoni, Ivan
中科院分区：
文献类型：
--
作者：
Fajgenbaum, David C;Hayday, Adrian C;Zanoni, Ivan
COVID-19的范围从无症状到呼吸衰竭和死亡。尽管诸如年龄和男性等特定的先前存在的疾病与结果不佳有关，但我们在很大程度上仍然不了解易于严重疾病的机制。在这项研究中，作者发现，在危及生命的Covid-19患者中，大约有10％具有对I型干扰素（IFNS）1的中和抗体1。他们证明这些抗体可以中和高浓度的相应IFN，并可以从IFN体外抑制SARS-COV-2感染。重要的是，抗IFN抗体与低水平的血清IFN有关。这些观察结果表明，由于抗体介导的IFN抑制作用，这些个体的疾病严重程度由于无法控制SARS-COV-2复制而导致疾病的严重程度。该研究提出了这类严重的Covid-19的特定治疗方法和诊断。
COVID-19 ranges from asymptomatic through to respiratory failure and death. Although specific pre-existing conditions such as age and male sex have been associated with poor outcomes, we remain largely ignorant of the mechanisms predisposing to severe disease. In this study, the authors discovered that approximately 10% of 987 patients with life-threatening COVID-19 harbored neutralizing antibodies to Type I interferons (IFNs)1. They demonstrated that these antibodies could neutralize high concentrations of the corresponding IFN and could rescue SARS-CoV-2 infection from inhibition by IFN in vitro. Importantly, anti-IFN antibodies were associated with low levels of serum IFN. These observations suggest that disease severity in these individuals results from a failure to control SARS-CoV-2 replication because of antibody-mediated IFN inhibition. The study suggests specific treatments and diagnostics for this class of severe COVID-19.